Hiten N. Patel

Hiten N. Patel

Auto-generated profile, based on publicly available information

Hiten N. Patel

University of Colorado Anschutz Medical Campus 2 Department of Bioengineering Aurora, Colorado

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
MRMaureen Hoen Rauhut
Maureen Hoen Rauhut
FAFahiima Abdullahi
Fahiima Abdullahi
JWJay Walters
Jay Walters
HPHiten N. Patel
Hiten N. Patel
DSDominik Stich
Dominik Stich
MRMercedes Rincon
Mercedes Rincon
Cell motility, characterized by random walk and exploratory search movement, enables effector CD8+ T cells to search for sparse antigen-specific cancer targets within a tumor. This is of special relevance for the treatment of solid cancers with adoptive T-cell receptor (TCR) T-cell therapy, in which administered effector CD8+ T cells recognize specific MHC-I–presented antigens. Cell motility requires cytoskeleton remodeling to facilitate cellular shape changes and movement. Herein, we show that increased mitochondrial Ca2+ levels are essential to reduce cytoskeleton stiffness of effector CD8+ T cells, leading to the acquisition of a polarized shape and high motility. IL21, but not IL7 or IL15, was able to raise mitochondrial Ca2+ levels in effector CD8+ T cells and increase their motility without affecting survival and proliferation. This increase in mitochondrial Ca2+ levels triggered by IL21 was driven by sustaining mitochondrial membrane potential through mitochondrial STAT3, independently of its transcriptional activity. Enhanced motility of effector CD8+ T cells led to superior killing efficacy of antigen-specific melanoma cells in vitro. Furthermore, enhanced mitochondrial Ca2+-mediated motility of adoptive TCR-specific effector CD8+ T cells resulted in superior antitumor efficacy of this treatment against solid tumors in vivo. Thus, enhancing effector CD8+ T-cell motility is a promising strategy to boost the efficacy of adoptive T-cell therapies against solid tumors.